Cytogenetic genotoxicity of anti-herpes purine nucleoside analogues in CHO cells expressing the thymidine kinase gene of herpes simplex virus type 1: comparison of ganciclovir, penciclovir and aciclovir.
The three anti-herpes nucleoside analogues ganciclovir, penciclovir and aciclovir were investigated as to their recombinogenic [sister chromatid exchange (SCE) inducing] and clastogenic activity in CHO cells expressing the thymidine kinase gene of HSV-1, which is a precondition of therapeutic activity of these drugs. The compounds were applied for the duration of one cell cycle and cytogenetic end-points were measured between 0 and 42 h after exposure. Although the nucleoside analogues are quite similar with respect to chemical structure, they differ basically in their genotoxic potency, aberration types induced as well as the time course of chromosomal damage. Aciclovir induced SCEs and chromosomal aberrations immediately after exposure but only in a concentration range much higher than that reached in blood plasma during anti-herpes therapy. The direct genotoxic activity is explained by the obligate chain terminating property of aciclovir upon incorporation into genomic DNA. On the other hand, genotoxic damage caused by ganciclovir and penciclovir is of the delayed type requiring at least one post-exposure cell cycle for its expression. Unlike aciclovir, ganciclovir is an extremely potent inducer of SCEs and chromosome breaks and translocations at concentrations far below those impairing the proliferative activity and triggering apoptosis of the target cells (as shown by our previous investigation). Penciclovir is essentially devoid of genotoxic activity. It induces SCEs only at cytotoxic/apoptotic concentrations, is only weakly clastogenic and induces premature chromosome condensation which appears to result from uncoupling of karyokinesis and cytokinesis. The genotoxic activity of ganciclovir is explained as due to repair processes triggered in the second post-exposure replication cycle at the sites of nucleoside analogue incorporation into genomic DNA. The findings have considerable implications with respect to the use of ganciclovir or other antiviral drugs in suicide gene therapy of malignant diseases.
Thust
R
R
Institute for Antiviral Chemotherapy, Medical Faculty, Friedrich Schiller University of Jena, Nordhäuser Strasse 78, Germany. thust@zmkh.ef.uni-jena.de
Tomicic
M
M
Klöcking
R
R
Wutzler
P
P
Kaina
B
B
D000212:Acyclovir / Q000031:analogs & derivatives* / Q000633:toxicity*; D000818:Animals; D000998:Antiviral Agents / Q000633:toxicity*; D016466:CHO Cells; D002875:Chromosomes / Q000187:drug effects; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D015774:Ganciclovir / Q000633:toxicity*; D006147:Guanine; D018259:Herpesvirus 1, Human / Q000378:metabolism*; D009153:Mutagens / Q000633:toxicity; D012854:Sister Chromatid Exchange / Q000187:drug effects; D013937:Thymidine Kinase / Q000235:genetics / Q000378:metabolism*; D013997:Time Factors
D000998:Antiviral Agents; D009153:Mutagens; C053539:penciclovir; D006147:Guanine; D013937:Thymidine Kinase; D015774:Ganciclovir; D000212:Acyclovir